ALK and neuroblastoma: The first phase I study of the New Approaches to Neuroblastoma Therapy Consortium (NANT2015-02) in children (NCT03107988) explored the use of loratinib in patients with ALK-driven refractory or relapsed neuroblastoma, demonstrating the drug’s safety profile and significant clinical activity.